• Low-dose levomepromazine, 6-25 mg/24 hours, has become more widely used and in some centres is prescribed before hyoscine butylbromide in inoperable chronically obstructed patients
• Although not available as an injection, olanzapine has been used in patienst with refractory nausea and vomiting, particularly when the much cheaper levomepromazine causes unacceptable sedation
Appetite stimulants are helpful in some patients. They should be stopped if no benefit is seen after 1 week. A corticosteroid (e.g. prednisolone, 15-30 mg o.d., dexamethasone, 2-4 mg o.d.) is sometimes useful, but the effect may last only a few weeks. A progestogen (e.g. medroxyprogesterone acetate, 400 mg o.d., megestrol, 160 mg o.d.) may have an effect lasting months and is generally associated with weight gain.
Appetite stimulants are inappropriate in patients with early satiety without concurrent anorexia. Associated physical features include altered taste, loose dentures causing pain and difficulty eating, pallor (anaemia), oedema (hypoalbuminaemia) and decubitus ulcers. Psychosocial consequences include ill-fitting clothes (increased feelings of loss and displacement), altered appearance (engenders fear and isolation), and difficulties in social and family relationships.
Causes of poor appetite in advanced cancer
Management -efforts should aimed at ameliorating the social consequences and physical complications.
• Do not weigh the patient routinely.
• Educate the patient and family about the risk of decubitus ulcers and the importance of skin care.
• If affordable, encourage the patient to buy new clothes to enhance self-esteem.
• Reline dentures to improve chewing and facial appearance; as a temporary measure, this can be undertaken at the bedside and lasts about 3 months.
• Supply equipment to help maintain personal independence (e.g. raised toilet seat, commode, walking frame, wheelchair).
Aggressive dietary supplementation via a nasogastric tube or intravenous hyperalimentation is of little value in reversing cachexia in advanced cancer because of the increased metabolic rate and abnormal metabolism. However, dietary advice is important, particularly if there are associated changes in taste. Some patients benefit psychologically from powdered or liquid nutritional supplements, and a few gain weight.
A trial of therapy with an appetite stimulant may help some patients. However, progestogens are expensive and should be used selectively. The effect of progestogens may be enhanced by concurrent use of ibuprofen, 1200 mg/day, or another NSAID.
Nausea and vomiting
Gastric stasis, intestinal obstruction, drugs and biochemical factors account for most cases of nausea and vomiting in advanced cancer; raised intracranial pressure accounts for less than 5%. It is important to identify the most likely cause in each patient, because treatment depends on the cause. On the basis of putative sites of action, it is possible to determine the anti-emetic drug of choice in various situations (Figure 3 ). The initial choice is generally metoclopramide, haloperidol, hyoscine butylbromide (or glycopyrronium) or cyclizine (or dimenhydrinate or promethazine). Other drugs may be necessary in some patients. 
Causes of cachexia in advanced cancer
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Corticosteroids are anti-emetics; they possibly act by reducing the permeability of the chemoreceptor trigger zone (area postrema) and of the blood-brain barrier to emetogenic substances, and by reducing the neuronal content of γ-aminobutyric acid (GABA) in the brain stem. Corticosteroids also reduce leu-enkephalin release in the brain stem and gastrointestinal tract.
Gastric stasis (delayed gastric emptying) accounts for about 25% of cases of nausea and vomiting.
Clinical features range from mild dyspepsia and anorexia to persistent severe nausea and large-volume vomiting (Figure 4) • If yes, provided the anti-emetic has been optimized, add or substitute a second anti-emetic 7 Anti-emetics for inoperable bowel obstruction are best given by CSCI. Levomepromazine (methotrimeprazine) is the exception; it can be given as a single subcutaneous injection o.n.
Step 1 -metoclopramide a ± dexamethasone b
Step 2 -levomepromazine c
Step • paraneoplastic autonomic neuropathy • retroperitoneal disease (leads to neural dysfunction)
• spinal cord compression • diabetic autonomic neuropathy. Epigastric distension and/or a succussion splash may be found on examination. A succussion splash requires the presence of more than 400-500 ml of fluid in the stomach and plenty of gas. Other features are as follows.
• Bowel sounds are generally normal but may be reduced if the stasis is opioid-induced.
• Flatus ('downwind') is unaffected.
• Bowel habit is not directly affected.
• If gastric stasis is associated with autonomic neuropathy, there may be other detectable autonomic abnormalities (e.g. orthostatic hypotension without compensatory tachycardia). Management centres on explanation and use of a prokinetic drug, preferably metoclopramide ( Figure 5 ). This generally leads to improvement and resolution of any succussion splash.
Warning -antimuscarinic drugs bind to receptors on intestinal muscle fibres and competitively block the effect of prokinetic drugs. As a general rule, prokinetic and antimuscarinic drugs should not be prescribed concurrently. However, domperidone and metoclopramide continue to exert an antagonistic effect at dopamine type 2 receptors in the chemoreceptor trigger zone in the brain stem, even when their prokinetic effect on the upper gut has been blocked.
Gastric outflow obstruction:
gastric stasis is sometimes associated with organic gastric outlet obstruction (cancer of the gastric antrum or external compression of the gastric antrum or duodenum by a tumour). This can cause major management difficulties. Each case needs individual evaluation and treatment. In most patients, the obstruction is incomplete -even without oral intake, the stomach needs to clear swallowed saliva (up to 1.5 litres/24 hours, but may be decreased by an antimuscarinic drug or dehydration) and basal gastric juices (about 1.5 litres/24 hours). Thus, if a patient is vomiting less than 2-3 litres/24 hours, something is passing the obstruction.
Management -the mainstay of management is generally an antisecretory drug. Hyoscine butylbromide, 80-120 mg/24 hours continuous s.c. infusion (CSCI), reduces gastric secretions by about one-half and reduces the volume of saliva, but this benefit is partly negated if the patient receives intravenous fluid. Hyoscine causes a dry mouth, which needs regular moistening. In the USA, where parenteral hyoscine butylbromide is unavailable, glycopyrronium, 800-1200 µg/24 hours, can be substituted.
H 2 -receptor antagonists (e.g. cimetidine, ranitidine) reduce both the acid content and the volume of gastric secretions and may provide additional benefit. In contrast, proton pump inhibitors reduce gastric acid production but do not significantly reduce the volume of gastric secretions. Somatostatin analogues, which are antisecretory but not antispasmodic, are used in some centres (e.g. octreotide, 300-600 µg/24 hours) alone or in conjunction with hyoscine butylbromide. Cost is a limiting factor.
A venting procedure (nasogastric tube or gastrostomy) is seldom necessary.
Obstruction: bowel obstruction in advanced cancer may be caused by one or more of the following:
• the cancer • previous treatment (e.g. adhesions, post-radiation ischaemic fibrosis) • drugs (e.g. opioids, antimuscarinics) • associated with debility (e.g. constipation)
• an unrelated benign condition (e.g. strangulated hernia).
Clinical features -in acute bowel obstruction, there is typically a single discrete lesion, whereas in chronic obstruction (persistent or remittent) there may be several sites of partial obstruction in both the small and the large bowel. Retroperitoneal disease may cause visceral neuropathy and functional obstruction. The quartet of symptoms and signs that indicate a diagnosis of acute intestinal obstruction (abdominal distension, pain, vomiting and 
Clinical features of gastric stasis
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MEDICINE constipation) may not all be present in chronic obstruction in advanced cancer. For example, distension may be minimal because of multiple intra-abdominal malignant adhesions. Bowel sounds vary from absent to overactive with borborygmi (tinkling bowel sounds are unusual). Some patients have diarrhoea rather than constipation. Surgical intervention should be considered when all of the following criteria are fulfilled.
• A single, discrete organic obstruction seems likely (e.g. postoperative adhesions, an isolated neoplasm).
• The patient's general condition is good (he does not have widely disseminated disease and has been independent and active).
• The patient is willing to undergo surgery. The following are contraindications to surgical intervention:
• previous laparotomy findings preclude successful intervention • intra-abdominal carcinomatosis (as shown by diffuse, palpable intra-abdominal tumours) • massive ascites, re-accumulating rapidly after paracentesis. In addition, weight loss of more than 9 kg is associated with a poor outcome after surgery.
Medical management -in patients in whom an operative approach is contraindicated, it is generally possible to relieve symptoms adequately with drugs ( Figure 3) . A nasogastric tube and intravenous hydration are seldom necessary. Management focuses primarily on the relief of nausea and vomiting. In patients without colic who continue to pass flatus, a prokinetic drug is the initial drug of choice. In patients with severe colic, prescribe an antisecretory and antispasmodic drug (e.g. hyoscine butylbromide, glycopyrronium).
Bulk-forming, osmotic and stimulant laxatives should also be stopped. A series of drug changes over several days may be necessary before optimum relief is achieved. Morphine or diamorphine should be given regularly for constant background cancer pain. In patients receiving parenteral metoclopramide or hyoscine butylbromide, the opioid can also be given by CSCI. A phosphate enema should be given if constipation is a probable contributory factor and a faecal softener prescribed (docusate sodium tablets, 100-200 mg b.d.).
Corticosteroids benefit some patients with inoperable intestinal obstruction. Because spontaneous resolution occurs in at least one-third of patients, it is important not to prescribe a corticosteroid too soon. Treat the symptoms as suggested above and then, after 5-7 days, if the obstruction has not settled, a trial of a corticosteroid for 3 days should be considered (e.g. dexamethasone, 8-16 mg s.c.). If there is improvement, either continue with the corticosteroid at a lower oral dose, or stop and review the need for long-term treatment.
Consider adding octreotide if vomiting is not reduced to once or twice daily by hyoscine butylbromide, 120-200 mg CSCI. Octreotide has an antisecretory effect throughout the alimentary tract. Octreotide can also be given by CSCI (e.g. 250-500 µg/24 hours, occasionally more). A reduction in intestinal contents reduces distension and thereby the likelihood of colic and vomiting.
A venting gastrostomy is seldom necessary for chronic obstruction in advanced cancer. Patients managed by drug therapy should be encouraged to drink and eat small amounts of their favourite beverages and food. Some patients find that they can tolerate food best in the morning.
